Live Breaking News & Updates on Seikagaku Corp

Stay updated with breaking news from Seikagaku corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the .
Bioventus, Inc.March 11, 2021 GMT
DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalation study of MOTYS (PTP-001) with Dr. Shailesh Patel, M.D. at Coastal Carolina Research Center, South Carolina. MOTYS is a placental tissue particulate comprised of amnion, chorion and umbilical cord tissue from full-term, healthy births and is provided sterile in micronized form. ....

United States , South Carolina , Shailesh Patel , Thomas Hill , Alessandra Pavesio , Mike Piccinino , Coastal Carolina Research Center , Exchange Commission , Company On Linkedin , Securities Exchange , Bioventus Inc , Bioventus Customer Service , Seikagaku Corp , Senior Vice President , Chief Science Officer , Active Healing , Securities Act , Securities Exchange Act , Risk Factors , Investor Relations , Products And Services , Government Regulations , Coronavirus Pandemic , Product Approvals , Product Testing , Diagnosis And Treatment ,